Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination dietary supplement** of **beta-hydroxy-beta-methylbutyrate (HMB)**, a metabolite of leucine, and **adenosine triphosphate (ATP)**, the primary energy carrier molecule in cells. HMB is commonly used to **support muscle health** by stimulating muscle protein synthesis (primarily via mTOR pathway activation [1][3][4]) and inhibiting muscle protein breakdown, including via ubiquitin-proteasome and autophagic-lysosomal systems[1]. ATP supplementation may enhance muscle performance and training adaptations by directly supporting muscle energy availability[2]. In clinical studies, this **combination has shown additive and synergistic effects**, leading to **increased lean body mass, strength, and power in trained individuals**, particularly during periods of high physical stress or overreaching[2]. Effects on recovery, reduced muscle damage, improved aerobic and anaerobic capacity, and attenuation of strength decline under fatigue have also been observed[2][4]. The combination is not classified as a pharmaceutical, but rather as a sports nutrition product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on beta-hydroxy-beta-methylbutyrate + adenosine triphosphate.